Ketamine discovery may lead to new antidepressants

We can now see what using ketamine for depression does to the brain.

The anaesthetic drug ketamine can quickly help people battling hard-to-treat depression — two decades worth of studies has made that clear — but scientists are still struggling to understand just how ketamine is able to do this.

Now, a new study is peeling back the curtain, revealing what the drug does in the brains of people with depression — and the knowledge could result in new antidepressants that boast the same benefits as ketamine without its negative side effects.

Ketamine for Depression

Every neuron in the brain has proteins called receptors on its surface, and chemicals called neurotransmitters bind to these receptors to trigger activity in the brain.

Low levels of the neurotransmitter serotonin have been linked to depression before, and scientists know that the chemical can bind to 14 different types of receptors.

Ketamine interacted with the receptors in a previously unknown way.

From their own past research, scientists at Sweden’s Karolinska Institutet knew that people with depression have a low density of serotonin 1B receptors. That inspired them to launch a study to explore how ketamine interacts with those receptors, in the hope that the information might help with the development of new antidepressants.

They enrolled 30 people with difficult-to-treat depression in their study, which was published in the journal Translational Psychiatry, and then used a technique called positron emission tomography (PET) to take images of their brains.

After that, they randomly split the participants into two groups. Twenty of the participants received an infusion of ketamine, while the other 10 received a placebo. Within 24 to 72 hours, each participant underwent another PET scan.

The Path to New Antidepressants

From the scans, the researchers learned that ketamine increased the number of serotonin 1B receptors in participants’ brains, but interacted with the receptors in a previously unknown way — the drug reduced the release of serotonin, but increased the release of another neurotransmitter linked to depression: dopamine.

Dopamine plays a major role in making people feel positive, which could help explain why ketamine is an effective antidepressant.

However, there’s a reason doctors don’t prescribe ketamine for depression more regularly — it’s a narcotic-classed drug with a high potential for addiction and abuse.

But now that we know more about what it does in the brain, instead of prescribing ketamine for depression, researchers could aim to develop new antidepressants that target serotonin 1B receptors in the same way — delivering the benefits of the drug without its negative baggage.

We’d love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at tips@freethink.com.

Related
ergot alkaloids
Morning glories may be a source of new psychedelics and medicines
Researchers have found that the symbiotic relationship between a fungus and a morning glory holds the potential for new psychedelic compounds and medicines.
cannabis cooking
Traditional Thai cannabis cooking is back on the menu
Cannabis cooking has long simmered in Thailand. With the ruling junta’s new drug policies, the traditional dish is now making its way onto restaurant plates.
long COVID treatment
Researchers are testing neural stimulation as a long COVID treatment
Small pilot trials of two different types of external electrical brain stimulation suggest the technique may work as a long COVID treatment.
Blocking an immune system protein helped mice recover from brain injury
Blocking an immune system molecule that accumulates after traumatic brain injury could significantly reduce the injury’s detrimental effects
Should psychedelics be patented
The issue of patents has riven the psychedelic field. A lawyer’s repository of psychedelic info may make sure the new field stays fair.
Up Next
Wearable
Subscribe to Freethink for more great stories